In a bid to expand its oncology portfolio, BioNTech has entered into a global licensing and collaboration agreement with OncoC4 to co-develop and commercialise a clinical stage candidate, ONC-392, as a monotherapy or combination therapy in multiple tumour indications. Under the terms of the agreement, OncoC4 will receive an upfront payment of US$200 M and is eligible to receive double-digit tiered royalties and milestone payments. BioNTech plans to combine ONC-392 with its own oncology candidates to test complimentary modes of action in an effort to boost therapeutic impact and expand the patient base.